导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 9.96% | 726/4773 |
| 近一周 | -2.67% | 2799/5462 |
| 近一月 | -5.45% | 3234/5421 |
| 近一季 | -4.13% | 1543/5209 |
| 近半年 | -0.24% | 1252/4920 |
| 近一年 | 16.31% | 616/4366 |
| 近两年 | 88.40% | 705/2954 |
| 近三年 | 48.43% | 561/2253 |
| 成立以来 | 93.87% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
2.29% 977/4961 |
19.06% 1325/5312 |
- - |
- - |
| 2025 | 34.28% 1067/4813 |
4.06% 1001/3635 |
3.09% 1173/4076 |
22.46% 1648/4524 |
2.22% 1038/4813 |
| 2024 | 5.67% 1819/3463 |
-3.73% 1553/2808 |
-4.86% 1574/3014 |
14.35% 1998/3129 |
0.89% 1154/3463 |
| 2023 | -6.61% 861/2656 |
6.02% 733/2280 |
-5.44% 1455/2385 |
-2.29% 655/2515 |
-4.66% 1133/2655 |
| 2022 | -16.33% 473/2207 |
-12.20% 587/1919 |
6.41% 704/2016 |
-11.70% 560/2113 |
1.42% 1274/2208 |
| 2021 | 16.23% 273/1822 |
-0.34% 356/1255 |
10.56% 452/1330 |
3.58% 401/1466 |
1.83% 787/1822 |
| 2020 | 35.31% 419/1250 |
-1.80% 241/1028 |
20.16% 283/1067 |
10.12% 586/1164 |
4.14% 865/1184 |
| 2019 | 31.20% 475/1092 |
29.44% 275/754 |
-7.73% 571/804 |
1.79% 359/850 |
7.93% 379/918 |
| 2018 | -25.86% 365/834 |
- - |
- - |
- - |
-10.64% 210/691 |
| 2017 | 11.88% 290/714 |
- - |
- - |
- - |
- - |
| 2016 | -7.32% 214/605 |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 创金合信中证500指数增强C VS. 长安沪深300非周期A(740101) |